<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Tme Pharma N.v. — News on 6ix</title>
    <link>https://6ix.com/company/tme-pharma-nv-1</link>
    <description>Latest news and press releases for Tme Pharma N.v. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 21 May 2026 16:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/tme-pharma-nv-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52cf4beedb30cb6f6bd0f.webp</url>
      <title>Tme Pharma N.v.</title>
      <link>https://6ix.com/company/tme-pharma-nv-1</link>
    </image>
    <item>
      <title>TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-convocation-of-the-2026-annual-general-meeting-of-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-convocation-of-the-2026-annual-general-meeting-of-shareholders</guid>
      <pubDate>Thu, 21 May 2026 16:00:00 GMT</pubDate>
      <description>TME PHARMA ANNOUNCES CONVOCATION OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS Berlin, Germany, May 21, 2026, 18.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases (TME), announces today that the annual general meeting of shareholders (AGM) of the company is convened at 10.00 a.m. CEST on 15 June 2026 at Sheraton Amsterdam Airport Hotel &amp; Conference Center, Sch</description>
    </item>
    <item>
      <title>TME Pharma publishes its annual financial results and annual report</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-publishes-its-annual-financial-results-and-annual-report-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-publishes-its-annual-financial-results-and-annual-report-1</guid>
      <pubDate>Thu, 30 Apr 2026 18:00:00 GMT</pubDate>
      <description>TME Pharma publishes its annual financial results and annual report Berlin, Germany, April 30, 2026, 20.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, announces today its financial results for the fiscal year ending December 31, 2025. The Annual Report 2025, as approved by the management and supervisory boards on April 30, 2025, is available on TME Pharma’s web</description>
    </item>
    <item>
      <title>TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-publication-of-nox-a12-triple-therapy-phase-12-expansion-arm-a-findings-from-gloria-trial-in-nature-communications-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-publication-of-nox-a12-triple-therapy-phase-12-expansion-arm-a-findings-from-gloria-trial-in-nature-communications-1</guid>
      <pubDate>Thu, 16 Apr 2026 06:05:00 GMT</pubDate>
      <description>TME Pharma Announces Publication of NOX-A12 “Triple Therapy” Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for braincancer and eye diseases, is pleased to announce a Nature Communications article on the results from the Phase 1/2 expansion Arm A cohort of the GLORIA trial testing NO</description>
    </item>
    <item>
      <title>TME Pharma extends financial runway to over 12 months</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-extends-financial-runway-to-over-12-months</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-extends-financial-runway-to-over-12-months</guid>
      <pubDate>Mon, 09 Mar 2026 07:01:00 GMT</pubDate>
      <description>TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that certain lenders have accepted to extend the maturity of their loan by a further 12 months. TME Pharma now has cash runway into Q2 2027. An agreement has been reached with certain lenders who participated i</description>
    </item>
    <item>
      <title>TME Pharma provides update on its activities</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-update-on-its-activities-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-update-on-its-activities-1</guid>
      <pubDate>Mon, 05 Jan 2026 07:01:00 GMT</pubDate>
      <description>TME Pharma provides update on its activities Berlin, Germany, January 5, 2025, 08.00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today updates on its research and development activities and its potential investment strategies. NOX-E36 developmentsTME Pharma announces the initiation of a subsequent study for NOX-E36 and the simultaneous termination of its coll</description>
    </item>
    <item>
      <title>TME Pharma announces receipt of agreements in principle to extend certain bond agreements</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-receipt-of-agreements-in-principle-to-extend-certain-bond-agreements-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-receipt-of-agreements-in-principle-to-extend-certain-bond-agreements-1</guid>
      <pubDate>Mon, 17 Nov 2025 07:01:00 GMT</pubDate>
      <description>TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announced today that certain holders of the bonds issued in May and August, 2025 have agreed in principle to extend the maturity of the bonds for a one year period. These bond holders, Diede va</description>
    </item>
    <item>
      <title>TME Pharma advances its new investment strategy and signs LOI with German resources company</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-advances-its-new-investment-strategy-and-signs-loi-with-german-resources-company-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-advances-its-new-investment-strategy-and-signs-loi-with-german-resources-company-1</guid>
      <pubDate>Wed, 05 Nov 2025 07:01:00 GMT</pubDate>
      <description>TME Pharma advances its new investment strategy and signs LOI with German resources company A further step toward investment diversification into potential cash-flow–generating assets A potential strategic investment in sustainable tailings reprocessing and environmental rehabilitation projects for precious metals with strong value-creation prospects. Upon successful completion of due diligence, the proposed transaction will be submitted to shareholders at an Extraordinary General Meeting.TME Ph</description>
    </item>
    <item>
      <title>TME Pharma publishes its semi annual results and half-year report</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-publishes-its-semi-annual-results-and-half-year-report-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-publishes-its-semi-annual-results-and-half-year-report-1</guid>
      <pubDate>Thu, 30 Oct 2025 20:00:00 GMT</pubDate>
      <description>TME Pharma publishes its semi annual results and half-year report Berlin, Germany, October 30, 2025, 21.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, publishes today its semi annual results and half-year report. The first half of the year was marked by TME Pharma&apos;s reorganization to a lower-cost outsourced staffing model. The results of this can be seen from H2 onwa</description>
    </item>
    <item>
      <title>TME Pharma Announces Date of Publication of Half Year Results and CEO Share Purchase</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-date-of-publication-of-half-year-results-and-ceo-share-purchase-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-date-of-publication-of-half-year-results-and-ceo-share-purchase-1</guid>
      <pubDate>Mon, 22 Sep 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, September 22, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, announces today that its half year results will be published on 30 October 2025. The closed period for insiders of the Company will start next week, 30 days before the publication of the half-year results on October 30, 2025.</description>
    </item>
    <item>
      <title>TME Pharma Completes August Financing and Publishes Cash Position</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-completes-august-financing-and-publishes-cash-position-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-completes-august-financing-and-publishes-cash-position-1</guid>
      <pubDate>Mon, 01 Sep 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, September 01, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that the transaction announced last August 25th has now been completed with €500k in cash received by the Company August 28th. The cash position of TME Pharma is up to €2.35M, showing the good progress of the new cost-efficient organization.</description>
    </item>
    <item>
      <title>TME Pharma to raise €500k through new bond issue and receives new notice of shareholding</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-to-raise-euro500k-through-new-bond-issue-and-receives-new-notice-of-shareholding-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-to-raise-euro500k-through-new-bond-issue-and-receives-new-notice-of-shareholding-1</guid>
      <pubDate>Mon, 25 Aug 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, August 25, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to announce that financial capacity will be improved through a new fund raise of €500,000 following on the May 2025 fundraise of €1.7M. The improved financial situation should strengthen TME Pharma&apos;s position in discussions with financial and strategic partners. It would also ena</description>
    </item>
    <item>
      <title>TME Pharma Provides Update About Additional Strategy</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-update-about-additional-strategy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-update-about-additional-strategy-1</guid>
      <pubDate>Tue, 29 Jul 2025 16:25:00 GMT</pubDate>
      <description>BERLIN, July 29, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to share an update regarding its strategic repositioning.</description>
    </item>
    <item>
      <title>TME Pharma: Termination of the Liquidity Contract</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-termination-of-the-liquidity-contract-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-termination-of-the-liquidity-contract-1</guid>
      <pubDate>Tue, 08 Jul 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, July 08, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye diseases, announced today the termination of the liquidity contract entered into with the brokerage firm INVEST SECURITIES (the &quot;Contract&quot;). The termination became effective on July 7, 2025 after market close.</description>
    </item>
    <item>
      <title>TME Pharma Announces New Treasury Investment Policy</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-new-treasury-investment-policy-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-new-treasury-investment-policy-1</guid>
      <pubDate>Mon, 30 Jun 2025 16:00:00 GMT</pubDate>
      <description>BERLIN, June 30, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer and eye-diseases, announced today that is has changed its treasury management investment policy to allow investment in higher-risk assets such as crypto-currency linked investments. The decision made, was possible because TME is now well positioned for the coming 12 months after it installed a new strategy and</description>
    </item>
    <item>
      <title>TME Pharma Provides Results of Final Exercise of Warrants Z</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-results-of-final-exercise-of-warrants-z-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-results-of-final-exercise-of-warrants-z-1</guid>
      <pubDate>Fri, 27 Jun 2025 16:00:00 GMT</pubDate>
      <description>BERLIN, June 27, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides results of the sixth and final exercise of Warrants Z and an update on the outstanding number of ordinary shares and Warrants Z as of the settlement date taking place today. The exercise of 1,948 Warrants Z has resulted in the issuance of 2,435 new shares</description>
    </item>
    <item>
      <title>TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-at-the-2025-annual-general-meeting-of-shareholders-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-at-the-2025-annual-general-meeting-of-shareholders-1</guid>
      <pubDate>Wed, 25 Jun 2025 16:00:00 GMT</pubDate>
      <description>BERLIN, June 25, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the unanimous approval of all resolutions submitted to its 2025 annual general meeting of shareholders (AGM), including the appointment of Diede van den Ouden as sole member of the board of directors and Chief Executive Officer as a successor to Ar</description>
    </item>
    <item>
      <title>TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-successful-next-step-in-its-nox-e36-ophthalmology-strategy-with-signature-of-option-framework-agreement-with-singapore-eye-research-institute-seri-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-successful-next-step-in-its-nox-e36-ophthalmology-strategy-with-signature-of-option-framework-agreement-with-singapore-eye-research-institute-seri-1</guid>
      <pubDate>Wed, 18 Jun 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, June 18, 2025--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617731821/en/</description>
    </item>
    <item>
      <title>TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-additional-details-on-the-debt-and-warrant-agreements-announced-on-21-may-that-extend-its-financial-visibility-by-12-months-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-provides-additional-details-on-the-debt-and-warrant-agreements-announced-on-21-may-that-extend-its-financial-visibility-by-12-months-1</guid>
      <pubDate>Tue, 27 May 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, May 27, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that its financial visibility will be extended into May 2026 through the issuance of debt via private contractual agreements with professional European investors (Investors) in exchange for €1.71 million in cash. The debt will be issued on May 28, 2</description>
    </item>
    <item>
      <title>TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-convocation-of-the-2025-annual-general-meeting-of-shareholders-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-announces-convocation-of-the-2025-annual-general-meeting-of-shareholders-1</guid>
      <pubDate>Mon, 26 May 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, May 26, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened at 03.00 p.m. CEST on June 25, 2025, at the offices of Freshfields LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.</description>
    </item>
    <item>
      <title>TME Pharma Extends Its Financial Visibility by 12 Months</title>
      <link>https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-extends-its-financial-visibility-by-12-months-1</link>
      <guid isPermaLink="true">https://6ix.com/company/tme-pharma-nv-1/news/tme-pharma-extends-its-financial-visibility-by-12-months-1</guid>
      <pubDate>Wed, 21 May 2025 06:00:00 GMT</pubDate>
      <description>BERLIN, May 21, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that its financial visibility will be extended into May 2026 through the issuance of regular bonds to professional investors with an aggregated nominal value of €2.05 million. The bonds were issued at a discount and with attached private warrants at</description>
    </item>
  </channel>
</rss>